These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9814953)

  • 21. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
    Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
    J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development.
    Betts MR; Gray CM; Cox JH; Ferrari G
    Expert Rev Vaccines; 2006 Aug; 5(4):505-16. PubMed ID: 16989631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AIDS vaccine: efficacy, safety and ethics.
    Veljkovic V; Veljkovic N; Glisic S; Ho MW
    Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fc receptor but not complement binding is important in antibody protection against HIV.
    Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
    Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The challenges of HIV vaccine development and testing.
    Burgers WA; Williamson C
    Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):277-91. PubMed ID: 15778116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A safe, effective and affordable HIV vaccine--an urgent global need.
    Joseph J; Etcheverry F; Alcami J; María GJ
    AIDS Rev; 2005; 7(3):131-8. PubMed ID: 16302460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress towards an AIDS mucosal vaccine: an overview.
    Yuki Y; Nochi T; Kiyono H
    Tuberculosis (Edinb); 2007 Aug; 87 Suppl 1():S35-44. PubMed ID: 17652028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine.
    Bhardwaj N; Walker BD
    Nat Med; 2003 Jan; 9(1):13-4. PubMed ID: 12514710
    [No Abstract]   [Full Text] [Related]  

  • 30. Cytokine profiles in HIV type 1 disease and protection.
    Shearer GM; Clerici M
    AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S149-52. PubMed ID: 9672232
    [No Abstract]   [Full Text] [Related]  

  • 31. Obstacles and progress toward development of a preventive HIV vaccine.
    Heyward WL; MacQueen KM; Jaffe HW
    J Int Assoc Physicians AIDS Care; 1997 Aug; 3(8):28-34. PubMed ID: 11364630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Towards an AIDS vaccine: the role of nonhuman primates.
    Nathanson N; Mathieson BJ
    J Med Primatol; 1999; 28(4-5):146-53. PubMed ID: 10593479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impetus for tracking nonhuman primate AIDS vaccine/live virus challenge studies.
    Warren JT
    J Med Primatol; 1992; 21(2-3):138. PubMed ID: 1433264
    [No Abstract]   [Full Text] [Related]  

  • 34. New directions for HIV vaccine development from animal models.
    McChesney MB; Miller CJ
    Curr Opin HIV AIDS; 2013 Sep; 8(5):376-81. PubMed ID: 23836045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress and challenges in therapies for AIDS in nonhuman primate models.
    Haigwood NL
    J Med Primatol; 1999; 28(4-5):154-63. PubMed ID: 10593480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetically identical primate modelling systems for HIV vaccines.
    Kent SJ; Lewis IM
    Reprod Fertil Dev; 1998; 10(7-8):651-7. PubMed ID: 10612472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mighty mice. Scientists are still improving the humanized mouse model but are optimistic about its future role in evaluating AIDS vaccine candidates.
    von Bubnoff A
    IAVI Rep; 2008; 12(5):1, 8-11. PubMed ID: 20213868
    [No Abstract]   [Full Text] [Related]  

  • 38. Accelerating HIV vaccine development using non-human primate models.
    Rahman MA; Robert-Guroff M
    Expert Rev Vaccines; 2019 Jan; 18(1):61-73. PubMed ID: 30526159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primate models for HIV vaccines.
    Schultz AM; Hu SL
    AIDS; 1993; 7 Suppl 1():S161-70. PubMed ID: 8363780
    [No Abstract]   [Full Text] [Related]  

  • 40. HIV vaccines: an attainable goal?
    Reynell L; Trkola A
    Swiss Med Wkly; 2012; 142():w13535. PubMed ID: 22389197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.